Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alzheimer's disease
Alzheimer's disease
Lilly says experimental Alzheimer's drug reduces amyloid in small study
Reuters
Mon, 04/3/23 - 09:54 am
Eli Lilly
Alzheimer's disease
clinical trials
remternetug
Coya Therapeutics reports data from Alzheimer’s Disease therapy trial
Clinical Trials Arena
Mon, 04/3/23 - 09:42 am
Coya Therapeutics
COYA 301
clinical trials
Alzheimer's disease
Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study
BioSpace
Thu, 03/30/23 - 11:02 pm
Biogen
Alzheimer's disease
clinical trials
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Endpoints
Thu, 03/30/23 - 10:02 am
Otsuka
Lundbeck
Alzheimer's disease
FDA
Rexulti
Alzheimer's disease agitation
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment
Fierce Biotech
Tue, 03/28/23 - 10:11 am
Vaxxinity
Alzheimer's disease
clinical trials
UB-311
Neurotechnology company Cognito Therapeutics scores $73M to study Alzheimer's device
Mobihealthnews
Thu, 03/23/23 - 09:19 pm
Cognito Therapeutics
Alzheimer's disease
Medtech
funding
neuromodulation
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
PM Live
Wed, 03/22/23 - 10:15 am
Roche
Eli Lilly
Alzheimer's disease
diagnostics
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Tue, 03/21/23 - 09:58 pm
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
Fri, 03/17/23 - 11:43 am
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Biogen's head of neurodegeneration leaves
Fierce Biotech
Fri, 03/17/23 - 10:03 am
Biogen
women executives
Aduhelm
Alzheimer's disease
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
Mon, 03/13/23 - 04:44 pm
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Sun, 03/12/23 - 09:40 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III
BioSpace
Thu, 03/9/23 - 11:46 am
Eli Lilly
Alzheimer's disease
solanezumab
clinical trials
Researchers announce highly accurate blood test for Alzheimer's Disease
Drugs.com
Wed, 03/8/23 - 09:53 pm
Durin Technologies
diagnostics
Alzheimer's disease
FDA sets July decision date for full approval of Leqembi
BioSpace
Mon, 03/6/23 - 12:11 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
Wed, 03/1/23 - 06:55 pm
ICER
Eisai
Leqembi
drug pricing
Alzheimer's disease
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease
Clinical Trials Arena
Tue, 02/28/23 - 11:02 am
Acumen Pharmaceuticals
clinical trials
Alzheimer's disease
ACU193
monoclonal antibodies
Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner
Endpoints
Mon, 02/27/23 - 10:19 am
Axsome Therapeutics
FDA
clinical trials
Alzheimer's disease agitation
Alzheimer's disease
AXS-05
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Thu, 02/23/23 - 04:27 pm
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »